Analytical Data
-
Gene name
CELA2A
- Application
-
Alternative Names
CELA2A；ELA2A；Chymotrypsin-like elastase family member 2A
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P08217
-
Expression Region
29-269aa
-
AA Sequence
VVGGEEARPNSWPWQVSLQYSSNGKWYHTCGGSLIANSWVLTAAHCISSSRTYRVGLGRHNLYVAESGSLAVSVSKIVVHKDWNSNQISKGNDIALLKLANPVSLTDKIQLACLPPAGTILPNNYPCYVTGWGRLQTNGAVPDVLQQGRLLVVDYATCSSSAWWGSSVKTSMICAGGDGVISSCNGDSGGPLNCQASDGRWQVHGIVSFGSRLGCNYYHKPSVFTRVSNYIDWINSVIANN
-
Molecular Weight
29.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The CELA2A protein, a member of the chymotrypsin-like serine protease family, plays a crucial role in various physiological processes, including digestion and immune response. Its gene, CELA2A, is primarily expressed in the pancreas, where it aids in the proteolytic processing of dietary proteins. In recent years, research has focused on the potential therapeutic applications of CELA2A, particularly in the context of pancreatic disorders and enzyme replacement therapies for conditions like exocrine pancreatic insufficiency. Additionally, the protein's involvement in inflammation and its possible impact on diseases such as pancreatitis has piqued interest in understanding its regulatory mechanisms and interactions with other proteins. Structural and functional studies on CELA2A are essential for elucidating its role in health and disease, enabling the development of targeted strategies for modulating its activity. Advances in recombinant DNA technology have facilitated the production of CELA2A as a recombinant protein, allowing for in-depth investigations into its enzymatic properties and interactions. This research could pave the way for innovative treatments based on the manipulation of CELA2A activity, offering new hope for patients suffering from pancreatic conditions and related gastrointestinal disorders.
